Cantor Fitzgerald Reiterates Overweight Rating for Zevra Therapeutics (NASDAQ:ZVRA)

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research note issued on Tuesday, Benzinga reports.

A number of other research firms have also recently issued reports on ZVRA. Maxim Group boosted their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. JMP Securities initiated coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Roth Mkm raised their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group reduced their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday, September 18th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Monday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Trading Up 3.9 %

NASDAQ:ZVRA opened at $7.12 on Tuesday. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $297.99 million, a price-to-earnings ratio of -5.27 and a beta of 1.94. The business’s 50-day moving average price is $7.18 and its two-hundred day moving average price is $5.77. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same quarter in the prior year, the firm posted ($0.15) EPS. On average, equities analysts expect that Zevra Therapeutics will post -1.59 earnings per share for the current year.

Insider Activity

In other Zevra Therapeutics news, Director Thomas Anderson bought 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, July 16th. The stock was acquired at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the acquisition, the director now owns 20,000 shares of the company’s stock, valued at approximately $136,200. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 22,000 shares of company stock worth $140,340 over the last ninety days. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Zevra Therapeutics by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares in the last quarter. Retirement Planning Co of New England Inc. increased its holdings in Zevra Therapeutics by 6.5% during the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock worth $2,246,000 after buying an additional 28,107 shares during the last quarter. Mystic Asset Management Inc. raised its position in Zevra Therapeutics by 11.9% during the second quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock worth $1,460,000 after acquiring an additional 31,650 shares in the last quarter. Armistice Capital LLC acquired a new stake in Zevra Therapeutics in the fourth quarter valued at $1,755,000. Finally, Bank of New York Mellon Corp grew its position in shares of Zevra Therapeutics by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock valued at $1,080,000 after acquiring an additional 21,231 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.